Non-Muscle Invasive Urothelial Carcinoma
Advertisement
Dr. Satkunasivam shares the inspiration for combining sasanlimab with BCG in patients with high-risk, BCG-naïve NMIBC.
Dr. Prasad provides overviews of ATLAS and ENVISION and opines on whether UGN-102 is a practice-ready alternative to TURBT.
Several urologists weigh in on BCG, its role in NMIBC treatment, shortages, and strategies to treat BCG-unresponsive disease.
The ATLAS study demonstrated the superiority of UGN-102 over TURBT for patients with low-grade, intermediate-risk NMIBC.
UGN-102 is a sustained-release, hydrogel-based formula that allows bladder tissue to be exposed to mitomycin longer.
Through molecular profiling, three different BCG response subtypes were found: BRS1, BRS2, and BRS3.
An observational study sought to determine variation in recurrence after TURBT between sites taking part in the RESECT study.
FDA approval of Adstiladrin for use in BCG-unresponsive NMIBC expands the armamentarium for treatment of high-risk NMIBC.
NMIBC-associated costs vary widely across types of treatments utilized, health systems, and regions of the country.
There is significant inter-site variation in recurrence of NMIBC after TRUBT in the RESECT study, according to new research.
Study results indicate an alternative strategy to radical cystectomy for comprehensive bladder-preserving therapy for MIBC.
No nonsurgical treatments currently exist for patients with NMIBC who did not respond to BCG therapy.
Patients with high-risk NMIBC who underwent TURBT from November 1993 to April 2019 were retrospectively evaluated.
A study analyzed effect of time to progression on OS in a cohort of patients with HR-NMIBC treated with intravesical BCG.
Is there an alternative regimen to BCG for NMIBC? The combination of intravesical gemcitabine and docetaxel may be.
Vignesh T. Packiam, MD discusses the current BCG shortage as well as potential substitutes such as gemcitabine and docetaxel.
IFNα and nadofaragene firadenovec can provide a new therapy approach for a disease with a significant unmet clinical need.
BCG plus nogapendekin alfa inbakicept may offer an enhanced treatment option for patients with high-risk NMIBC.
Andrea Necchi, MD, speculates on the applicability of pembrolizumab monotherapy for BCG-unresponsive NMIBC.
Kyle M. Rose, MD, describes how cell-free DNA is used to detect MRD prior to repeat-transurethral resection in NMIBC.
Advertisement
630 Madison Ave.
Manalapan, NJ 07726
© 2023 Mashup Media, LLC. All rights reserved.